Pulp regeneration by transplantation of dental pulp stem cells in pulpitisa pilot clinical study

A dentist tells a patient their tooth is unsaveable. The pulp is infected, irreversibly inflamed, and the only option is a root canal — a procedure that hollows the tooth out and leaves it biologically dead for the rest of their life. Pause on that word: dead. Then consider that five patients in Japan just got a different answer. To understand why that matters, you have to know what dental pulp actually does. Nakashima and colleagues describe it precisely: the pulp provides immunological surveillance that protects the tooth from infection, it drives rapid reparative dentin formation to shield the inner tooth from damage, and it contributes to the tensile strength that keeps a tooth from fracturing. The pulp is simultaneously the tooth's sensory organ, its repair crew, and part of its structural support system. When irreversible pulpitis destroys that tissue, the standard treatment is pulpectomy — complete removal. The authors are blunt about the alternative: in severe irreversible pulpitis, the whole pulp is infected, and there is no effective treatment other than whole pulp removal. But what fills that space afterward is an inert material, not living tissue. The tooth loses its defenses, its repair capacity, and some of its strength. Microleakage from the crown can cause apical lesions. Vertical root fracture becomes more likely. The tooth is saved in one sense and compromised in another. That is the problem this research set out to solve. Nakashima and colleagues developed what they call mobilized dental pulp stem cells, or MDPSCs — a clinical-grade subset of mesenchymal stem cells isolated from a patient's own discarded tooth. The source material is teeth that would otherwise be thrown away. Within one hour of extraction, the tooth is transported to a good manufacturing practice facility at a temperature between zero and ten degrees Celsius, cut open, and the pulp tissue is enzymatically digested to release primary cells. Those cells are cultured in a medium containing ten percent autologous serum — the patient's own serum — and colonies appear within seven to fifteen days. Then comes the mobilization step: granulocyte colony-stimulating factor, known as G-CSF, is applied to select the migratory, trophic subset of cells. These are the MDPSCs. They are then expanded and cryopreserved at one million cells per milliliter. The quality control process is extensive. The final cell product at passage seven was characterized by flow cytometry for surface markers. Across the five patients, mean expression was 98.7 percent for CD29, 99.5 percent for CD44, and 94.3 percent for CD105 — all markers of mesenchymal stem cell identity. The endothelial marker CD31 was nearly absent at 0.6 percent, confirming the cells were not contaminated with vascular cells. Mean total cell yield, excluding one compromised preparation, was 15.5 million cells, with post-thaw viability of 83 percent. Sterility, mycoplasma, virus panels, and endotoxin measurements all came back clean. Chromosomal safety was assessed by karyotype analysis at passages nine or ten, with no significant structural abnormalities found. Before any of this moved to humans, canine studies showed MDPSC transplants regenerated pulp tissue occupying roughly seventy to eighty percent of root canal volume with nerve extension into dentin within four weeks — and adding G-CSF to the MDPSCs produced significantly larger volumes of regenerated tissue and greater nerve growth than either component alone. With that preclinical foundation, Nakashima and colleagues enrolled five patients — three men and two women with a mean age of twenty-eight point six years — all diagnosed with irreversible pulpitis in a single-root canal. The inclusion criteria were narrow: no tooth fracture, sound structure above the alveolar bone margin, no periapical radiolucency, and the availability of a discarded tooth to supply pulp tissue. After pulpectomy and standard root canal preparation, one million cryopreserved MDPSCs were thawed, washed, and suspended in forty microliters of clinical-grade atelocollagen — a purified collagen scaffold — together with three hundred nanograms of G-CSF. Half that suspension was delivered into the prepared root canal through a fine cannula, a gelatin sponge was placed at the canal orifice, and the tooth was sealed. Five patients were monitored at one, two, four, twelve, and twenty-four weeks with blood work, urine chemistry, twelve-lead electrocardiograms, electric pulp testing, MRI, and cone beam computed tomography. Now for what grew back. Before transplantation, all five root canals were electric pulp test negative — meaning no sensory response whatsoever. By four weeks, four of the five patients converted to a positive electric pulp test response. The electric pulp test works by delivering a low electrical stimulus to the tooth surface; a positive response means viable tissue in the canal can transmit that signal, almost certainly through sensory nerve fibers. Four of five patients responding within a month is a striking early signal of re-innervation. Magnetic resonance imaging provided an independent check. The team measured the relative signal intensity of regenerated tissue in the root canal against surrounding dentin on T2-weighted images. At twenty-four weeks, the relative signal intensity values across the five patients were 0.8, 0.9, 0.9, 0.7, and 0.9. Normal dental pulp, in untreated control teeth, showed comparable values. Because MRI highlights water- and blood-filled soft tissues, this match in signal intensity suggests the regenerated material had imaging characteristics consistent with native pulp — meaning restored vascularity and tissue composition, not just a scar. Cone beam computed tomography, which can resolve low-density pulp space and denser newly formed dentin, showed lateral dentin deposition along the canal walls in three of the five patients. Two of those cases had measurable reductions in root canal volume: one patient's canal volume dropped from 0.0143 to 0.0125 cubic centimeters, and another's from 0.0110 to 0.0081. That matters because new dentin narrowing the canal is a functional outcome — it helps protect the tooth from fracture, which is precisely the vulnerability that pulpectomy creates. Across all five patients and all twenty-four weeks of follow-up, there were no adverse events, no systemic toxicity on blood or urine tests, and no abnormalities on electrocardiogram. The cell products themselves were sterile and endotoxin-free. So three independent lines of evidence — electrical sensibility, MRI signal, and hard-tissue dentin formation — all pointed in the same direction. A tooth that was declared biologically finished showed signs of a living interior. Here is where honesty matters. This is a pilot study of five patients followed for six months. It demonstrates safety and feasibility. It does not prove broad clinical efficacy, and the authors say so directly. The electric pulp test is subjective — it tells you viable tissue is present, not how much or how healthy. MRI and cone beam computed tomography were informative here but need validation as standardized, quantitative endpoints in larger trials. Only three of the five patients showed cone beam computed tomography evidence of dentin formation. The sample is too small to draw population-level conclusions, the follow-up too short to know what these teeth look like at five or ten years, and the good manufacturing practice manufacturing process — with its controlled-rate cryopreservation, multiple quality screens, and autologous serum requirements — is not yet ready to scale. What the study does establish is that this path is open. Autologous MDPSCs can be safely isolated from a patient's own discarded tooth, expanded to clinical scale under good manufacturing practice conditions, and transplanted back into a pulpectomized root canal without adverse events. The regenerated tissue has functional electrical responses, MRI characteristics matching normal pulp, and in three cases evidence of new dentin formation — all within twenty-four weeks. In Nakashima and colleagues' words, human MDPSCs are safe and efficacious for complete pulp regeneration in this pilot study. For decades, irreversible pulpitis ended in the same place: a hollowed tooth, an inert fill, a biological dead end. This work shows the possibility of a different ending — one where the tooth stays alive. That is worth following. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.